Drug Approval | August 13, 2021
USFDA grants distinct indication for Chronic Sleep Disorder
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
